TRI and the University of Arkansas, Fayetteville on Wednesday announced they are offering telehealth research pilot grants of up to $15,000, with an additional $5,000 for projects that include a UAF collaborator. For more information and to download the Request for Applications (RFA):
Download RFA.
The Translational Research Institute (TRI) today issued a request for applications for its 2014 pilot awards program. Awards are $50,000 maximum and have a 1-year time limit. The letter of intent is due June 2, and full applications are due Aug. 4, 2014. New this year is a requirement for a letter of approval from the IRB or IACUC with the full application. Learn more here.
Contact: Kelly Bulloch, kwbulloch@uams.edu, 501.686.5417.
Lee Ann MacMillan-Crow, Ph.D., a professor in the Department of Pharmacology/Toxicology, has been named director of TRI’s Novel Methodologies and Pilot Studies Program.
As director, MacMillan-Crow will play a key role in the promotion of translational research through the administration of TRI’s annual pilot funding program. TRI funds translational research at all levels, from basic science to clinical trials of new therapeutics, and community-based interventions. The program has awarded $3.6 million to UAMS researchers over the last five years.
MacMillan-Crow is program director of the Interdisciplinary Toxicology PhD Program and a standing member on the Surgery, Anesthesiology, and Trauma Study Section at NIH. Her laboratory has been funded by the NIH since 2001 and has a long-term interest in oxidant generation and mitochondrial damage during renal ischemia/reperfusion, as it relates to transplantation injury.
In addition, her research is examining the therapeutic potential of several agents to block renal mitochondrial injury during warm and cold ischemia, using rat, porcine, and a human model of transplantation. This research has led to a Use Patent and pending Phase II Small Business Grant from NIH. Another recent area of study in collaboration with Philip Mayeux, Ph.D., supported by an NIH RO1 grant, is related to the role that mitochondrial superoxide has on mitochondrial and renal damage during sepsis.
MacMillan-Crow earned her doctorate from the University of Alabama at Birmingham in 1994 and moved to UAMS in 2003. She has served as primary mentor to 10 graduate students and served on 18 dissertation committees.
Letters of intent for TRI’s 2014 Pilot Award Program and applications for the 2014 KL2 Career Development Awards are both due June 2.
Pilot Awards
The pilot awards are $50,000 maximum and have a 1-year time limit. Full applications are due Aug. 4, 2014. New this year is a requirement for a letter of approval from the IRB or IACUC with the full application. Learn more here. Contact: Kelly Bulloch, kwbulloch@uams.edu, 501.686.5417.
KL2 Awards
Benefits of the two-year KL2 Award program for UAMS junior investigators include:
Up to $52,000 each year for salary support
Up to $25,000 each year in research funds
Travel and graduate-level tuition support
Eligible candidates are those with professional doctorates committed to academic careers in translational research. View details of the program. Download TRI’s 2014 Request for Applications. Contact: behudson@uams.edu.
Today, the National Center for Advancing Translational Sciences (NCATS) released its first annual report, available on the NCATS website. NCATS administers the Clinical and Translational Science Award (CTSA) program, whose funding supports the work of UAMS’ Translational Research Institute (TRI).
The NCATS report highlights major milestones and achievements during 2012 and 2013. It also showcases how NCATS’ innovative programs, initiatives and collaborations are helping to advance translational sciences for the broader research community.
“Every NCATS project is designed to address what I call the 3Ds: develop new approaches, technologies, resources and models; demonstrate their usefulness; and proactively disseminate the data, analysis and methodologies so that other scientists can implement them,” said NCATS Director Christopher P. Austin, M.D. “Though NCATS is still relatively new, early successes showcase how our distinctive approaches can help solve some of the most challenging problems in translational sciences.”
Read the NCATS Annual Report.
May 1 – TRI Request for Applications Will Be Released
June 2 – Letter of Intent Due
June 16 – Full Applications Invited
August 4 – Full Applications Due
Awards are $50,000 maximum with a 1-year time limit.
New for 2014
IRB or IACUC approval letter required with full application
Letter of intent and application instructions will be available May 1.
Please contact Kelly Bulloch at 501.686.5417 or KWBulloch@uams.edu.
The National Institutes of Health has announced a policy change that allows researchers to submit an application as a new proposal even though the proposal had been previously reviewed by an NIH study section. The notice number is NOT-OD-14-074 (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-074.html).
The next Showcase of Medical Discoveries featuring telehealth is June 4, 4-5:30 p.m., in the Winthrop P. Rockefeller Cancer Institute 10th Floor Rotunda. The event will include the work of investigators from UAMS and the University of Arkansas, Fayetteville. The College of Medicine is joined in this Showcase by TRI and the UAF as co-sponsors, and a new pilot funding mechanism co-sponsored by TRI and UAF will be announced at the event.
This showcase is open to all interested faculty, students, staff and invited guests. The series’ ongoing goals include fostering communication and collaboration between investigators and increasing awareness of exciting research in Arkansas. View a flyer about the event.
Elvin Price, Pharm.D., Ph.D., a 2013 UAMS Translational Research Institute (TRI) KL2 Career Development awardee, was recently selected to serve as an associate scientific advisor for Science Translational Medicine, sister publication of the journal Science.
Price, an assistant professor in the College of Pharmacy, is the first scientist from UAMS to earn the selection in the publication’s five-year history. It was based on his writing sample and a nomination from Robert McGehee, Ph.D., who directs TRI’s Research Education, Training and Career Development Program. Price is among just 26 early career researchers nationally selected as associate scientific advisors for 2014.
Price will write nine editorials for the publication this year. The April issue of Science Translational Medicine includes his first editorial on cardiac ischemia titled: “Dancing with the Scars: Choreography of the Macrophage Two Step After Myocardial Infarction.”
“This is a really cool opportunity,” Price said. “I get to work with senior editors from the science family, and I can already see the benefits to the quality of my writing for applications that I will submit in June and to the manuscripts that I’m working on.”
McGehee, dean of the UAMS Graduate School, noted that the editors at Science Translational Medicine were looking for an inaugural set of investigators who could be associate editors and bring interests and expertise across multiple disciplines in recognizing and moving translational medicine forward.
“Dr. Price was a natural and perfect choice,” McGhee said. “His training background in clinical pharmacy as a Pharm.D., furthered by his Ph.D. training in cardiovascular pharmacogenomics and personalized medicine, provide him with a very unique translational skill set for such a role, and it is very rewarding the editors recognized this.”
“These are the kinds of opportunities that we really like to see our KL2 Scholars get involved with,” he said.
Price is one of 13 promising early career researchers selected over the last five years for a KL2 award by the Translational Research Institute. The award provides salary and research support to help jump-start the research programs of junior investigators like Price.
Price is studying promising genetic predictors that he hopes will help doctors prescribe the right cardiovascular medicines for their patients.
Science Translational Medicine, established in 2009, is an interdisciplinary medical research journal established by the journal Science and the American Association for the Advancement of Science. It aims to advance the field of translational medicine, which promotes the transfer of basic science discoveries and experimental approaches of modern science to the alleviation of human disease.
The March issue of The TRIbune is now online. The newsletter features new TRI Director Laura James, M.D., and Associate Director Cornelia Beck, Ph.D., R.N., who built their research careers studying the opposite ends of the human lifespan.
Return to Newsroom >>
News Archive >>
